OSIR - Osiris Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
19.04
0.00 (0.00%)
At close: 4:00PM EDT

19.04 -0.02 (-0.10%)
After hours: 4:00PM EDT

Stock chart is not supported by your current browser
Previous Close19.04
Open19.03
Bid18.99 x 800
Ask19.06 x 900
Day's Range19.03 - 19.06
52 Week Range7.01 - 19.30
Volume567,846
Avg. Volume176,600
Market Cap657.419M
Beta (3Y Monthly)0.47
PE Ratio (TTM)17.81
EPS (TTM)1.07
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date2015-10-14
1y Target Est4.00
Trade prices are not sourced from all markets
  • ACCESSWIRE4 days ago

    SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Osiris Therapeutics, Inc. – OSIR

    BALA CYNWYD, PA / ACCESSWIRE / March 15, 2019 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Osiris Therapeutics, Inc. (''OSIR'' ...

  • SHAREHOLDER ALERT: WeissLaw LLP Investigates Osiris Therapeutics, Inc.
    PR Newswire4 days ago

    SHAREHOLDER ALERT: WeissLaw LLP Investigates Osiris Therapeutics, Inc.

    NEW YORK , March 15, 2019 /PRNewswire/ --  WeissLaw LLP   is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Osiris Therapeutics, Inc. ("OSIR" ...

  • GlobeNewswire5 days ago

    OSIRIS THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout

    WILMINGTON, Del., March 14, 2019 -- Rigrodsky & Long, P.A.: Do you own shares of Osiris Therapeutics, Inc. (NASDAQ GM: OSIR)? Did you purchase any of your shares prior to.

  • PR Newswire6 days ago

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Osiris Therapeutics, Inc. - OSIR

    NEW YORK , March 13, 2019 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • PR Newswire7 days ago

    ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Osiris Therapeutics, Inc.

    NEW YORK , March 12, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Osiris Therapeutics, Inc. (NASDAQ: OSIR) and its board of directors for breach of fiduciary duty concerning ...

  • GlobeNewswire7 days ago

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Osiris Therapeutics, Inc. to Smith & Nephew plc is Fair to Shareholders

    NEW YORK, March 12, 2019 -- The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Osiris Therapeutics, Inc. (“Osiris”.

  • American City Business Journals7 days ago

    Osiris to be acquired by British medical device company for $660.5M

    Columbia-based Osiris is coming off a tumultuous three-year period in which four CEOs left the company and several former executives faced criminal charges for fraud.

  • Business Wire7 days ago

    OSIRIS THERAPEUTICS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout

    Do you own shares of Osiris Therapeutics, Inc. (NASDAQ GM: OSIR)? Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Osiris Therapeutics, Inc. (“Osiris” or the “Company”) (NASDAQ GM: OSIR) regarding possible breaches of fiduciary duties and other violations of law related to the Company’s entry into an agreement to be acquired by Smith & Nephew plc (“Smith & Nephew”) (NYSE: SNN) in a transaction valued at approximately $660.5 million.

  • Reuters7 days ago

    Smith & Nephew to buy Osiris in regenerative products push

    The deal will help Smith & Nephew better compete with bigger rivals such as U.S.-based Johnson & Johnson as Osiris's products, including skin and bone grafts, complements its portfolio of wound care products. "Greater presence in the fast growing regenerative medicine market enhances our portfolio and will help immediately accelerate our wound management business," Smith & Nephew Chief Executive Officer Namal Nawana said.

  • Reuters7 days ago

    Britain's Smith & Nephew to buy Osiris in regenerative products push

    Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as the British medical products maker looks to bulk up in an area that is quickly growing. The deal will help Smith & Nephew better compete with bigger rivals such as U.S.-based Johnson & Johnson as Osiris's products, including skin and bone grafts, complements its portfolio of wound care products. "Greater presence in the fast growing regenerative medicine market enhances our portfolio and will help immediately accelerate our wound management business," Smith & Nephew Chief Executive Officer Namal Nawana said.

  • Reuters7 days ago

    Smith & Nephew to buy Osiris Therapeutics for $660 mln

    British medical products maker Smith & Nephew Plc said on Tuesday it would buy U.S.-based regenerative medicine maker Osiris Therapeutics for $660 million, as it looks to boost profit margins and find ...

  • GlobeNewswire7 days ago

    Osiris Therapeutics, Inc. Enters Agreement to be Acquired by Smith & Nephew plc

    Osiris Therapeutics, Inc. (OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, today announced that it has entered into an agreement and plan of merger with Smith & Nephew plc pursuant to which Smith & Nephew will acquire Osiris for $19.00 per share in cash, a total of approximately $660.5 million in cash. Peter Friedli, Chairman of the Board and co-founder of Osiris, said, “This is a very good outcome for Osiris’ shareholders.

  • GlobeNewswire19 days ago

    Predictive Technology Group Names Jay M. Moyes to Its Board of Directors

    Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named to the company’s Board as an independent director, effective immediately. Moyes brings more than 30 years of healthcare industry expertise in senior-level financial positions and has significant governance experience from Board memberships at publicly traded healthcare companies. “We are delighted to attract a professional of Jay’s caliber as we build out Predictive’s Board with proven leaders to support our strategy of bringing proprietary genetic-based diagnostics and therapeutics to market,” said Bradley C. Robinson, CEO of Predictive Technology Group.

  • Atlanta's MiMedx sued by competitor Osiris Therapeutics for alleged 'deceit, trickery, and unfair methods'
    American City Business Journals26 days ago

    Atlanta's MiMedx sued by competitor Osiris Therapeutics for alleged 'deceit, trickery, and unfair methods'

    Troubled Atlanta biomedical company MiMedx Group Inc. (OTC: MDXG) is being sued by competitor Osiris Therapeutics Inc. (Nasdaq: OSIR), who claims MiMedx "jeopardized Osiris’s business by deceit, trickery, and unfair methods." In a complaint filed Feb. 20 in federal court in Atlanta, Columbia, Md.-based Osiris contends MiMedx and a distributor it formerly owned, Stability Biologics, breached several obligations they owed to Osiris, which had been a customer of Stability before it was bought by MiMedx in January 2016. Osiris and MiMedx are direct competitors in the market for regenerative cellular and tissue-based products used to treat injuries and wounds.

  • Business Wire2 months ago

    Hagens Berman: Notice to Osiris Therapeutics, Inc. Investors: Less than One Week Left to File Claims to Receive Part of $18.5 Million Settlement

    National investor-rights law firm Hagens Berman Sobol Shapiro LLP reached an $18.5 million settlement on behalf of investors in Osiris Therapeutics, Inc. who purchased shares between May 12, 2014 and November 16, 2015.

  • Business Wire2 months ago

    Hagens Berman Notifies Osiris Therapeutics, Inc. Investors of Class Action Settlement and January 30, 2019 Claims Deadline

    National investor-rights law firm Hagens Berman Sobol Shapiro LLP reached a settlement on behalf of investors in Osiris Therapeutics, Inc. who purchased shares between May 12, 2014 and November 16, 2015.

  • Is Abraxas Petroleum Corp. (NASDAQ:AXAS) A Good Stock To Buy?
    Insider Monkey3 months ago

    Is Abraxas Petroleum Corp. (NASDAQ:AXAS) A Good Stock To Buy?

    We know that hedge funds generate strong, risk-adjusted returns over the long run, therefore imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors. With billions of dollars in assets, smart money investors have to conduct complex analyses, spend many resources and use tools that are not always […]

  • GlobeNewswire4 months ago

    Osiris Therapeutics, Inc. Appoints Samson Tom, PhD, MBA to Serve as President and Chief Executive Officer

    Osiris Therapeutics, Inc. (OSIR), a regenerative medicine company focused on developing and marketing products for wound care, orthopedics, and sports medicine, is pleased to announce that its Board of Directors appointed Samson Tom, PhD, MBA to serve as President and Chief Executive Officer, effective November 26, 2018. Dr. Tom was at Osiris from 2003 to 2011, where he held several leadership positions spanning multiple functional areas including Quality, Operations, Clinical Development, and Product Development. Subsequently, he served as Group Director, Biosurgery Research & Development at Ethicon, Inc. (a Johnson & Johnson company).

  • Associated Press4 months ago

    Osiris: 3Q Earnings Snapshot

    The Columbia, Maryland-based company said it had net income of 12 cents per share. Earnings, adjusted to account for discontinued operations, came to 11 cents per share. The developer of treatments using ...

  • Benzinga6 months ago

    The Daily Biotech Pulse: Morphosys Expands Collaboration, Osiris Announces Product Launch, Argenx To Offer Shares

    The following are top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Sept. 17.) Champions Oncology Inc (NASDAQ: CSBR ) Emergent Biosolutions ...